BioFluidica is developing innovative technologies for the isolation and analysis of rare, circulating biomarkers in the blood. The company's first platform has the capacity to isolate circulating tumor cells, exosomes and cfDNA from the blood with unprecedented recovery and purity. The technology is based on patented microfluidics designs and has been clinically validated for 6 different cancer types including Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Breast Cancer, Multiple Myeloma and AML. Additionally, stroke detection and infectious disease identification have obtained clinical validation using the BioFluidica test.
